Find therapies in clinical trials near you – page 8

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)